The National Institute for Health and Care Excellence (NICE) has today published final guidance to the NHS in England and Wales on the use of bortezomib (Velcade) for the treatment of multiple myeloma. The guidance confirms the response-rebate scheme which will allow patients at first relapse who show a full or partial response to bortezomib to carry on with the treatment, fully funded by the NHS, and patients who show no or minimal response to be taken off the drug and the drug costs refunded by the drug's manufacturer.

2007/056 NICE guidance on bortezomib (Velcade) is a win-win solution for multiple myeloma patients and the NHS 24 October 2007 (42.6Kb 15sec @ 28.8Kbps)

Adobe Acrobat reader required.